| Mgmt Confidence | High confidence in OCU400 power analysis showing 93.2% power at 20% response. |
|---|---|
| Margin Trends | R&D expenses rose to $12.5M from $11.1M year-over-year. |
| Pricing Power | Bahamas EAP pricing expected to match US commercial pricing levels. |
| Segment Growth | OCU410 for GA identified as the largest commercial opportunity. |
| New Clients | Exclusive OCU400 license for MENA with Roots Pharma; $4M upfront/milestones. |
| Capex & Debt | Cash balance of $84.6M expected to support runway into 2028. |
| Regulatory | OCU400 received provisional approval in Bahamas under LARDA; full approval expected year-end. |
| Commentary | Modifier gene therapy platform is gene-agnostic, addressing underlying biology across multiple networks. |
| New Launches | Established European presence to support pre-commercial activities and clinical development. |
Growth
Q3 2026 operating expenses were $19.7M; net loss per share improved to $0.01.
Outlook
Targeting three BLA filings by 2028; OCU400 Phase 3 top-line data expected Q1 2027.
Risks
Management pivoted on Stargardt interim efficacy, citing small sample size and baseline heterogeneity for lack of modification.
The company's earnings call, NASDAQ: OCGN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Ocugen, Inc.: key numbers
- Share price
- $0.7730Close, Nov 16
- Market cap
- $262M
- Shares outstanding
- 339.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ocugen, Inc.
All →Ocugen Licensing Deal with Celairis Therapeutics Holdings Pty Ltd Worth $7.1M
Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.
- Value
- $7.1M
- Counterparty
- Celairis Therapeutics Holdings Pty Ltd
- Term
- 20 years
Ocugen Q3 2026 Results: Net Loss of $3.6M, Loss Narrows
Ocugen, Inc. reported total assets of $108.1 million as of September 30, 2026, a significant increase from $43.5 million at the end of 2025, primarily driven by $59.6 million in new short-term investments. The company is currently advancing its Phase 3 trial for OCU400 and Phase 2/3 trial for OCU410ST while maintaining its status as a non-accelerated filer and smaller reporting company.
- Key figure
- Net loss $3.6M
Ocugen Financial Results
Ocugen reported Q3 2026 financial results, highlighting a cash position of $84.6 million with an expected runway into 2028. The company advanced its gene therapy pipeline, including the initiation of the Phase 3 ArMaDa3 trial for OCU410 and receiving provisional approval for OCU400 in The Bahamas.
- Term
- Q3 2026
“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.”
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
“As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
Ocugen Investor Presentation
Ocugen, Inc. filed a formal investor presentation deck for October 2026 detailing its strategic pipeline and clinical milestones. The company is targeting three Biologics License Applications (BLAs) by 2028 for its gene therapy candidates OCU400, OCU410, and OCU410ST, which address major blindness diseases.
Ocugen Licensing Deal with Roots Pharmaceutical Company WLL Worth $259M
Ocugen granted Roots Pharmaceutical an exclusive license to commercialize OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa. Ocugen will receive up to $4 million in upfront and development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen also entered into a commercial supply agreement to manufacture the product for Roots.
- Value
- $259M
- Counterparty
- Roots Pharmaceutical Company WLL
- Term
- 20 years from first commercial sale
Ocugen CEO Shankar Musunuri Sells $500K of Stock
Shankar Musunuri, CEO, sold 525,991 shares of Ocugen, Inc. at $0.95 a share, worth $500K in total on Oct 9, 2026. Shares held after the trade: 1,030,771 (-5.3%).
- Value
- $500K
- Shares
- 525,991
- Average price
- $0.9500
- Role
- CEO
- Holding change
- -5.3%
- Trade date
- Oct 9, 2026